http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Jambaldorj, Enkthuya (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Complete genome sequence of Janibacter indicus TT2, isolated from the human ear skin
Jargal Jambaldorj,Munkhtsatsral Ganzorig,KYOUNG LEE 한국미생물학회 2020 미생물학회지 Vol.56 No.4
Janibacter indicus TT2 was isolated from the human ear skin for its ability to degrade t-octylphenol polyethoxylates (Triton X-100). Herein, we report the whole-genome sequence and gene annotations of J. indicus TT2. This strain possessed one circular chromosome comprising 3,663,756 bp, with the G + C content of 71.0%, encoding 3,452 protein-coding genes, two ribosomal RNA operon copies, and forty-nine tRNA genes. In addition, we found that strain TT2 had dehydratase and hydroxylase genes in its genome that might be responsible for removal of the ethylene oxide units and oxygenation of the t-octylphenol moiety of Triton X-100, respectively.
-
Jeong, Jong Cheol,Jambaldorj, Enkthuya,Kwon, Hyuk Yong,Kim, Myung-Gyu,Im, Hye Jin,Jeon, Hee Jung,In, Ji Won,Han, Miyeun,Koo, Tai Yeon,Chung, Junho,Song, Eun Young,Ahn, Curie,Yang, Jaeseok Wolters Kluwer Health, Inc. All rights reserved. 2016 Medicine Vol.95 No.5
ABSTRACT: Combination therapy of intravenous immunoglobulin (IVIG) and rituximab showed a good transplant rate in highly sensitized wait-listed patients for deceased donor kidney transplantation (DDKT), but carried the risk of antibody-mediated rejection. The authors investigated the impact of a new combination therapy of bortezomib, IVIG, and rituximab on transplantation rate.This study was a prospective, open-labeled clinical trial. The desensitization regimen consisted of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m), and 4 doses of bortezomib (1.3 mg/m). The transplant rate was analyzed. Anti-Human leukocyte antigen (HLA) DRB antibodies were determined by a Luminex solid-phase bead assay at baseline and after 2, 3, and 6 months in the desensitized patients.There were 19 highly sensitized patients who received desensitization and 17 patients in the control group. Baseline values of class I and II panel reactive antibody (%, peak mean fluorescence intensity) were 83 ± 16.0 (14952 ± 5820) and 63 ± 36.0 (10321 ± 7421), respectively. Deceased donor kidney transplantation was successfully performed in 8 patients (42.1%) in the desensitization group versus 4 (23.5%) in the control group. Multivariate time-varying covariate Cox regression analysis showed that desensitization increased the probability of DDKT (hazard ratio, 46.895; 95% confidence interval, 3.468–634.132; P = 0.004). Desensitization decreased mean fluorescence intensity values of class I panel reactive antibody by 15.5% (20.8%) at 2 months. In addition, a liberal mismatch strategy in post hoc analysis increased the benefit of desensitization in donor-specific antibody reduction. Desensitization was well tolerated, and acute rejection occurred only in the control group.In conclusion, a desensitization protocol using bortezomib, high-dose IVIG, and rituximab increased the DDKT rate in highly sensitized, wait-listed patients.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
